Ten patients in whom severe haemorrhage from the bladder persisted after clot evacuation and fulguration were treated by continuous irrigation with 1% alum solution. Bleeding ceased in 8 patients ...

The most common immunotherapy for treating early-stage bladder cancer is the Bacillus Calmette-Guerin (BCG) vaccine treatment. If that fails, the only other alternative is surgery to remove the entire ...

The most common immunotherapy for treating early-stage bladder cancer is the Bacillus Calmette-Guerin (BCG) vaccine treatment. If that fails, the only other alternative is surgery to remove the ...

for TAR-200 for the treatment of patients with Bacillus Calmette-Guérin (BCG)-unresponsive high-risk non-muscle-invasive bladder cancer (HR-NMIBC) with carcinoma in situ (CIS), with or without ...

New Drug Application Initiated with U.S. FDA for TAR-200, the First and Only Intravesical Drug Releasing System for Patients with BCG-Unresponsive High-Risk Non-Muscle-Invasive Bladder Cancer January ...

MANILA, Philippines – President Ferdinand Marcos Jr. on Wednesday stressed the need for “big dams” in the country and vowed to provide enough funds for irrigation programs. Marcos made the ...

New York: Pfizer Inc. has announced positive topline results from its pivotal Phase 3 CREST trial evaluating sasanlimab, an investigational anti-PD-1 monoclonal antibody (mAb), in combination with ...

Bladder cancer is one of the most common type of cancer in the UK, with over 10,000 people diagnosed every year. And it is the eighth most common cancer in men. The University of Sheffield and ...

1 “TAR-200 represents a novel interventional approach for the treatment of localized bladder cancer where today, unfortunately, options are limited and include antiquated BCG therapy or radical ...

University of Sheffield experts said the drug durvalumab could reduce the recurrence of operable bladder cancer by a third Medical experts in Sheffield have hailed as a "game changer" trials of a ...

Medical experts in Sheffield have hailed as a "game changer" trials of a drug that could reduce the recurrence of bladder cancer. Using the immunotherapy drug durvalumab before and after surgery ...

An FDA application for TAR-200 to treat BCG-unresponsive high-risk non-muscle-invasive bladder cancer is under real-time oncology review, expediting access to this potential treatment. The FDA has ...